An innovative small molecule for promoting neuroreparative strategies by Colabufo, Nicola Antonio et al.
  
 University of Groningen
An innovative small molecule for promoting neuroreparative strategies
Colabufo, Nicola Antonio; Contino, Marialessandra; Cantore, Mariangela; Berardi, Francesco;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Colabufo, N. A., Contino, M., Cantore, M., Berardi, F., Perrone, R., Tonazzi, A., ... Luurtsema, G. (2018).
An innovative small molecule for promoting neuroreparative strategies. RSC Advances, 8(10), 5451-5458.
https://doi.org/10.1039/C7RA11812K
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
























































































View Journal  | View IssueAn innovative smaDipartimento di Farmacia-Scienze del Farm
Orabona 4, 70125, Bari, Italy. E-mail: nicol
bBiofordrug srl, Dipartimento di Farmacia-
“Aldo Moro”, via Orabona 4, 70125, Bari, I
cCNR-IBIOM (Institute of Biomembrane, Bioe
via Amendola 165/A, 70126 Bari, Italy
dDepartment BEST (Biologia, Ecologia, Scien
Molecular Biotechnology, University of Cala
eDipartimento di Bioscienze, Biotecnologie e
Moro”, via Orabona 4, 70125, Bari, Italy
fUniversity of Groningen, University Medical
Medicine and Molecular Imaging, Hanzeple
Cite this: RSC Adv., 2018, 8, 5451
Received 26th October 2017
Accepted 22nd January 2018
DOI: 10.1039/c7ra11812k
rsc.li/rsc-advances
This journal is © The Royal Society of Call molecule for promoting
neuroreparative strategies
Nicola Antonio Colabufo, *ab Marialessandra Contino,a Mariangela Cantore,b
Francesco Berardi,a Roberto Perrone,a Annamaria Tonazzi,ce Lara Console,d
Maria Antonietta Panaro,e Heli Savolainenf and Gert Luurtsemaf
In this study, a new regenerative strategy to treat several neurodegenerative diseases is suggested by the
use of a multitarget approach induced by our small molecule, MC111. Considering the importance of P-
gp and BCRP expression on stem cell diﬀerentiation and the involvement of TLR4 on neurodegeneration
processes, we investigated the eﬀect of MC111, belonging to our library of P-gp active compounds on:
(i) TLR4 signaling; (ii) P-gp and BCRP activity and expression; (iii) neurite sprouting. The observed ﬁndings
exerted by MC111, open a new scenario for a multitarget and regenerative approach in
neurodegenerative diseases encouraging the in vivo evaluation of MC111 as new tool in neuroreparative
medicine.Introduction
The challenge of this study is to suggest a new multitarget and
regenerative approach disclosing new perspectives in neurode-
generative diseases. “Regenerative medicine” may provide an
innovative treatment for many human disorders by the use of
stem cells (SC). SC are a unique population of cells able to self-
renew and diﬀerentiate into diﬀerent cell types1 and they can be
transplanted or manipulated in vivo to restore missing cells.
Therefore, considering the capability of self-renewal and
diﬀerentiation into a range of tissues of Neural Stem Cells
(NSCs), SC-mediated therapy can be considered, at the present,
the goal in cell replacement therapies in diﬀerent pathological
conditions such as in inammation, neurodegeneration,
immunomodulation and stimulation of endogenous recovery.
Several reports demonstrated the expression of some ATP-
binding cassette (ABC) transporters such as P-glycoprotein
(P-gp, ABCB1) and Breast Cancer Resistance Protein (BCRP,
ABCG2) in human neural stem/progenitor cells (hNSPCs).2,3
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hemistry 2018localization in NSCs on their diﬀerentiation and proliferation
has been highlighted.2 Indeed, P-gp and BCRP expression
represents a feature of proliferating stem cells and not of
quiescent cells and their activities are involved in tissue
regeneration mechanism, and in the protection from cell death
under stress conditions.2
During the early developmental step, embryonic stem cells
need a “protective barrier” due to the presence of ABC trans-
porters pivotal in maintaining SC in an undiﬀerentiated state;
by contrast, their downregulation may induce an increased
diﬀerentiation of NSCs.2
Indeed, Blood–Brain Barrier (BBB) endothelial cells produce
soluble factors inuencing the diﬀerentiation of NSPCs and in
physiological conditions these factors, as substrates of ABC
pumps, are eﬄuxed by these transporters. When the expression
of these proteins decreases, as in the early stage of Alzheimer's
Disease (AD), these factors are not eﬄuxed altering the micro-
environment of stem cell niche and cellular homeostasis with
functional alterations in neurogenesis.1 Therefore, since the
expression of ABC transporters present in hNSPCs can be
modulated, these proteins are the key for promoting hNSPCs
self-renewal without diﬀerentiation. This link existing between
ABC transporters present in NSCs can explain the potential of
NSCs as therapeutic strategy in several brain disorders such as
AD, Parkinson and Huntington's diseases through an endoge-
nous activation. Moreover, an additional target identied in the
early stage of AD is represented by Toll-Like Receptor 4
(TLR4);4,5 it is widely reported that microglia activation via TLR4
is closely associated to a number of neurodegenerative disor-
ders including AD and ischemic stroke.6 In the senile plaques
observed in the brain of AD patients, microglia is present in an





















































































View Article Onlinepathogenesis of the disease. Microglia activation results in the
overproduction of NO, oxygen free radicals, proteases, adhesion
molecules and pro-inammatory cytokines responsible for the
degenerative process.7 AD patients and AD animal models
display increased expression of CD14 (a co-receptor for TLR4),
TLR4 and TLR2 8 in response to the presence of Ab and TLR4
mutation induces a decreased microglial activation, an increase
in Ab deposits and exacerbation of cognitive decits.4 There-
fore, as Ab deposits occur, microglia is activated via TLR4
signaling to block Ab deposition and to preserve cognitive
functions from Ab-mediated neurotoxicity.9 On the basis of
these evidences, microglia activation via TLR4 in early stages of
AD pathogenesis exerts a neuroprotective eﬀect, and TLR4
pathways may be considered a potential therapeutic targets.
With all these aspects in mind, we hypothesized a multi-
targets drug, TLR4 inducer and P-gp/BCRP upregulating agent,
simultaneously able to protect neurons by AD progression and
in the meantime to activate the neuroreparative steps by
maintaining stem cells in undiﬀerentiated state. By a large
screening of our P-gp/BCRP ligands library, we selected a small
molecule named MC111.10 MC111 prole has been deepened
and the following activities have been studied: (i) the inuence
on TLR4 signaling; (ii) the activity towards P-gp and BCRP; (iii)
the eﬀect on neurites sprouting.Results
MC111 inuence on TLR4 signaling and on P-gp and BCRP
expression
MC111 was found able to increase TLR4 and P-gp expression
(Fig. 1A) in SW480 human colon adenocarcinoma cells; TLR4
involved pathway has been deeply studied considering also the
eﬀect on other targets such as the nuclear factor NF-kB. TLR4
pathway involves the activation of NF-kB, as depicted in Fig. 1B;
in unstimulated cells, NF-kB is sequestered in cytoplasm as
inactive form by interacting with inhibitor of NF-kB (IkB)
proteins. TLR4 stimulation by ligands leads to IkB phosphory-
lation with the release of NF-kB in the nucleus leading to the
transcription of many pro-inammatory genes encoding cyto-
kines. In order to verify the existence of a link between
ABCB1–TLR4 and MC111 activity, as depicted in Fig. 1C, P-gp
(ABCB1) has been silenced and TLR4 expression detected in
the presence of MC111; the ligand activity on P-gp expression
has been evidenced aer TLR4 silencing. The experiments
demonstrated that MC111 activity on TLR4 and P-gp was
reciprocally dependent from the expression of the two proteins.
Moreover, also MC111 activity prole towards BCRP has
been investigated in MCF7 cells where BCRP, but not P-gp, is
highly expressed.MC111 activity towards P-gp and BCRP
To assess how the expression and the activity of these proteins
is inuenced byMC111, the molecule has been probed in three
cell lines (MCF7, hCMEC/D3 and Colo320 cells) in presence of
radiolabeled P-gp and BCRP substrates, [3H]verapamil and [11C]
MC150, respectively (unpublished results, formula depicted in5452 | RSC Adv., 2018, 8, 5451–5458supplementary materials). The substrates verapamil and
MC150 are diﬀerently radiolabelled since verapamil is
commercially available while MC150, belonging to our library,
has been radiolabelled for in vivo PET analysis (studies in
progress). The results demonstrated that MC111 increased the
eﬄux of both substrates conrming that our ligand is an
inducer of expression and also activity of the two pumps.
The immunostaining analysis on MCF7 cells demonstrated
an increased BCRP expression already aer 2 hours of MC111
exposition. In hCMEC/D3 cells, the same eﬀect on BCRP
expression was found aer 72 h treatment with MC111.
The inuence of MC111 on P-gp activity was assessed by
subcellular fractionation experiments in Colo320 cells where
the protein is highly present. In the presence of MC111, an
increased [3H]verapamil eﬄux was observed. Moreover, also the
eﬄux of a P-gp/BCRP radiolabeled substrate ([11C]-MC150) was
increased by MC111 pre-treatment in Colo320 cells indicating
induced BCRP activity.Neuroregeneration
We investigated the role of MC111 on dissociated primary
sensory neurons with particular emphasis on the neurite growth
changes. The eﬀects of MC111 on Dorsal Root Ganglion (DRG)
neurons in comparison to those cultured in a basic culture
medium in the absence of NGF (negative control) or in the
presence of NGF (positive control) was studied.11 DRG neurons
culture was carried out following 3 diﬀerent experimental
conditions: Bottenstein and Sato's Medium (BSM) alone; BSM + 1
mg ml1 NGF and BSM + 1 mM MC111. Neurite outgrowth from
DRG living neurons aer 72 h culture was observed under phase
contrast microscope and images of the cells were digitized
(Fig. 2A–F). From a qualitative analysis of the coverslips it
appeared, that few cells cultured in BSM alone sprouted neurites
(Fig. 2A andD) while the presence of either NGF (Fig. 2B and E) or
MC111 (Fig. 2C and E) in the culture medium induced evident
changes in neurite outgrowth of DRG neurons.
Cell were then xed and immunostained with bIII tubulin
antibodies (Fig. 2G and J no addition; Fig. 2H and K NGF added;
Fig. 2I and LMC111 added). Subsequent quantitative analysis of
the DRG neurons was performed. Four parameters were
measured: (1) % of cells containing neuritis respect to cells
without neurites that resulted: 30% 8.7 (only BSM); 52% 3.5
(BSM + NGF); 59%  7.1 (BSM +MC111) (Fig. 3A). These results
pointed out that both NGF and MC111 treatments induced
a signicant increase (P < 0.01) of neurons sprouting neurites in
comparison to control. (2) Length of longest neurite: signicant
diﬀerences are evident between control neurons and neurons
treated either with NGF or MC111; the length of the longest
neurite was indeed similar between neurons treated with NGF
or MC111 (Fig. 3B). (3) The number of neurites/cell: 1.6  0.9
(only BSM); 8 2.6 (BSM + NGF); 2.2 0.8 (BSM +MC111). Only
treatment with NGF was eﬀective in inducing a signicantly
higher number of neurites respect to the control (Fig. 3C). (4)
Total neurite length: 884 467 mm (only BSM); 4848  1363 mm
(BSM + NGF); 2116  494 mm (BSM + MC111). Both NGF and
MC111 induced a signicant increase in the sum of the totalThis journal is © The Royal Society of Chemistry 2018
Fig. 1 Histograms and densitometric WB analysis from SW480 cells. (A) TLR-4 and P-gp expression in SW480 cells ((C) unstimulated cells; (LPS)
cells stimulated with 1 mg ml1 LPS; (MC111) cells stimulated with 250 mM MC111. (B) Activation of NF-kB performed by analysis of active
phosphorylated form (p-IkB). (C) Modulation of TLR-4 expression after P-gp silencing (left) and P-gp expression after TLR-4 silencing (right),
respectively (siC: P-gp or TLR-4 silenced unstimulated cells; siLPS: P-gp or TLR-4 silenced cells stimulated with 1 mg ml1 LPS; P-gp or TLR-4





















































































View Article Onlineneurite length, that was indeed higher in the presence of NGF
(Fig. 3D).
These results show that MC111 induces a relevant neurite
sprouting with respect to the negative control but with diﬀerent
characteristics compared to NGF. Following treatment with
NGF, a signicant increase in total neurite number developed
from each neuron was detected. The eﬀect ofMC111was mainly
represented by a moderate increase in neurite number and
a great increase in the percentage of neuron spouting neurites
with respect to the total neuron number, comparable with the
increase obtained in the presence of NGF. The morphology of
neurite sprouting from cells treated withMC111 is more similar
to the physiological one, i.e. originating from the cellular body,
that divides into two neurites (Fig. 2C, F, I and L). The obser-
vation that MC111 induces the growth of fewer but longer
neurites in comparison to NGF, deserves particular attention in
the perspective of peripheral nerve regeneration and repair
(Fig. 4).Experimental
Materials and method
MC111 inuence on TLR4 signaling and on P-gp and BCRP
expressionThis journal is © The Royal Society of Chemistry 2018Cell cultures. To explore how MC111 inuences TLR4
signaling we used SW480 cells since they express P-gp and can
signal through TLR4.12 The human colon adenocarcinoma cell
line SW480 (ICLC HTL99017-Interlab Cell Line Collection) was
cultured on Leibovitz-15 medium supplemented with 10% fetal
bovine serum, 100 U ml1 penicillin, 100 mg ml1 streptomycin
and L-glutamine (2 mM; Life Technologies-Invitrogen).
Cultures were maintained at 37 C in a humidied atmo-
sphere containing 5% CO2 and expanded in tissue culture asks
(75 cm2; BD Biosciences), changing daily the medium.
The cells were seeded in six-well cell culture plates at 5  105
cells per well and cultured to reach 80% conuency.
Cell treatments. Cell cultures were treated with lipopolysac-
charide (LPS) from Salmonella typhimurium (Sigma-Aldrich) or
with MC111 (concentration ranging from 500 nM to 250 mM).
Preliminary experiments were performed in order to establish
the optimal dose (1 mg ml1) of LPS and MC111 (250 mM) and
time of exposure to LPS (48 h). Untreated cells were used as
control.
Treatment of cell cultures with small interfering RNA. Cell
cultures (60–70% conuence) were submitted to P-gp or TLR-4
specic small interfering RNA (siRNA) using commercial kits
(Santa Cruz Biotechnology) according to the manufacturer's
protocol. Cells were incubated with 60–80 pmols of siRNA forRSC Adv., 2018, 8, 5451–5458 | 5453
Fig. 2 Representative images of Dorsal Root Ganglia (DRG) neurons after 72 h culture. (A–F) Phase contrast microscopy of DRG neurons
cultured in the presence of BMS alone (A and D), BMS + 1 mg ml1 NGF (B and E), BMS + 1 mM MC111 (C and F). (G–L) Immunocytochemical






















































































View Article Online5–7 h at 37 C, using a transfection reagent. Then, 1 ml of
complete medium (2) was added and cells incubated for
24 h. The day aer, medium was replaced with fresh culture
medium and cells were incubated for 48 h before experimental
treatments. Aer this time, cells were submitted to LPS or
MC111 treatment as indicated above.5454 | RSC Adv., 2018, 8, 5451–5458Electrophoresis. Aer treatment as previously described, cells
were washed twice in PBS, detached with ice-cold PBS, collected
and centrifuged at 600g for 10 min. The supernatant was
removed and the pellet was harvested and lysed by ice-cold lysis
[1% (v/v) Triton X-100, 20mMTris–HCl, 137mMNaCl, 10% (v/v)
glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl uorideThis journal is © The Royal Society of Chemistry 2018
Fig. 3 Quantiﬁcation of DRG neurons neurite outgrowth after 72 h culture. BSM (white columns), BMS + 1 mg ml1 NGF (grey columns), BMS + 1
mM MC111 (black columns). (A) Percentage of neuron sprouting neurites; (B) length of longest neurite; (C) neurite number per cell; (D) sum of





















































































View Article Online(PMSF), 20 mM leupeptin hemisulfate salt, 0.2 U ml1 aprotinin
(all from Sigma Aldrich)] for 30 min on an ice-bath. Lysate was
centrifuged at 13 800g for 20 min at 4 C. The protein concen-
tration in the supernatant was spectrophotometrically deter-
mined by Bradford's protein assay and the lysate was subjected
to SDS-PAGE (NuPage Electrophoresis System-Invitrogen).
Protein samples were diluted 1 : 4 by NuPage LDS Sample
Buﬀer 4 and 1 : 10 by NuPage Sample Reducing Agent
(500 mM dithiothreitol (DTT) at 10 concentration) andFig. 4 MC111 activities proﬁle.
This journal is © The Royal Society of Chemistry 2018underwent 10 min at 70 C. Protein (30 mg lane-1) and pre-
stained standards (Invitrogen) were loaded on 4–12%Novex Bis-
Tris Midi gel 1.0 mm precast gels (Life Technologies-
Invitrogen).
Western blotting. Aer electrophoresis, the resolved proteins
were transferred from the gel to nitrocellulose membranes
using iBlot Dry Blotting System A (Life-Technologies-
Invitrogen). Then, membranes were blocked by PBS, (pH 7.2)





















































































View Article Onlinefor 1 h and washed three times with 0.1% Tween 20-PBS (T-PBS).
Specic proteins were detected using optimal concentration of
primary antibodies, rabbit polyclonal anti human TLR-4
(1 : 200) or mouse monoclonal anti-human P-glycoprotein
(MDR) (1 : 500). The binding of antibodies was detected with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG
followed by chemiluminescence detection (Pierce, Perbio,
Rockford, USA). The b-actin protein level was used as a protein
loading control in western blotting.
Densitometric analysis. The visualized bands obtained aer
immunoblotting experiments, were submitted to densitometric
analysis using id image analysis soware (Kodak Digital
Science). b-actin was used for normalization of the immuno-
blotting products. Results were expressed as relative protein
expression to b-actin.
Statistical analysis. Results were statistically examined by
analysis of variance (one-way ANOVA) and a p-value < 0.05 was
considered statistically signicant.
MC111 activity on P-gp and BCRP. Commercially available
chemicals were purchased from Sigma-Aldrich. [3H]-Verapamil
(specic activity 80 Ci mmol1, 1 mCi ml1, solved in ethanol)
was supplied by Biotrend. The primary anti-P glycoprotein
antibody for mouse [JSB-1] and primary anti-BCRP/ABCG2
antibody for rat [BXP-53] were supplied by Abcam, UK or USA.
The secondary antibody of P-gp anti-Mouse Alexa Fluor® 647
and secondary antibody of BCRP Anti-Rat Alexa Fluor® 488 were
supplied by Abcam, UK or USA. Subcellular fraction buﬀer was
prepared by the combination of the following reagents: 250 mM
sucrose; 20 mM HEPES-hydroxyethyl piperazineethanesulfonic
acid (pH 7.4) (Life Technologies); 10 mM KCl (Merck); 1.5 mM
MgCl2 (Merck); 1 mM EDTA-ethylenediaminetetraacetic acid
(Merck); 1 mM EGTA-ethylene glycol tetraacetic acid (Sigma-
Aldrich); DTT (dithiothreitol) (Sigma-Aldrich); and protease
inhibitor cocktail (Sigma-Aldrich).
Transwell™ 12-insert systems with tissue culture treated
polycarbonate membrane, 8.0 mm pore size and 6.5 mm diam-
eter inserts and Transwell™ 12-insert systems with tissue
culture treated polyester membrane, 0.4 mm pore size and
12 mm diameter inserts were purchased from Corning Incor-
porated, USA. All reagents and chemicals used in this study are
of analytical grade. Radioactivity measurements in cell studies
were done using an automated gamma counter (Compugamma,
LKB Wallac).
Cell lines. The colon cancer cell line of human origin, Colo320
and the human breast adenocarcinoma, MCF-7 (both kindly
provided by the Medical Oncology Department of the UMCG,
Netherlands) were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with fetal calf serum (10%)
in a humidied incubator at 37 C, 5% CO2 atmosphere. The
cerebral microvascular endothelial cells of human origin,
hCMEC/D3 (supplied by Institut Cochin, Paris, France), were
cultured in RPMI 1640 supplemented with 10% fetal calf serum
(FCS) Fetal Calf Serum (10%), penicillin (1%), hydrocortisone
(1.4 mM), acid ascorbic (5 mg ml1), HEPES (10 mM), bFGF (1 ng
ml1) in a humidied incubator at 37 C, 5% CO2 atmosphere.
The glioma cell line of rat origin C6 was cultured in Dulbecco's
Modied Eagle Medium (DMEM) supplemented with 10% FCS5456 | RSC Adv., 2018, 8, 5451–5458in a humidied incubator at 37 C, 5% CO2 atmosphere. Twice
a week, the cells were harvested with trypsin and medium was
changed.
Immunostaining of hCMEC/D3 and MCF7 cells. hCMEC/D3 or
MCF7 cells were grown on gelatin-coated glass coverslips and
exposed toMC111 for 24 and 72 h. Aer washing with cold PBS,
cells were blocked with 1% PBS–BSA for 15 minutes; xed with
4% paraformaldehyde (PFA) for 20 minutes; permeabilized with
0.2% Triton-X-100 for 10 minutes and blocked with 1% PBS–
BSA for 15 minutes. The cells were incubated with 1% primary
anti-P glycoprotein antibody or primary anti-BCRP/ABCG2
antibody in 1% PBS–BSA for 1 hour. The cells were then
blocked in 15 minutes in 1% PBS–BSA and incubated in the
dark with 0.02% secondary antibody for P-gp or BCRP for 30
minutes. Nuclear localization was also determined by staining
with 1 mg ml1 of DAPI. In between steps, the cells were washed
3 times with PBS. The expression of proteins was visualized by
Leica DM6000B uorescence microscope.
Subcellular fractions for detecting fraction-specic inducer
uptake. Subcellular fractionation was performed at diﬀerent
concentration of inducer (5–300 mM) to establish the minimum
concentration to reach the maximum uptake of [3H]-verapamil.
Aerwards, this concentration was used to perform subcellular
fractionation at diﬀerent time points (20 min to 24 hours). The
protocol for subcellular fractionation available on the website of
Abcam®, https://www.abcam.com, was modied. At the time of
use, 25 ml of stock subcellular fractionation buﬀer were taken
and 25 ml of 1 mMdithiothreitol and 125 ml of protease inhibitor
cocktail were added. The cells were treated with MC111 in
a concentration range of 5–300 mM followed by addition of 0.2 ml
[3H]verapamil (0.2 mCi). Aer 30 min incubation the medium
was removed and the cells were harvested from the plate using
trypsin and transferred into clean Eppendorf tubes containing
RPMI 1640 medium for neutralizing the trypsin. To obtain the
cell pellet, the cell suspension was centrifuged at 9000 rpm for
2 min. Supernatant was discarded and 500 ml of cold subcellular
fractionation buﬀer was added to each cell pellet. Pellets were
homogenized using 25 G needle and 1 ml syringe, distinct for
each pellet, and kept on ice for 20 minutes. Aer homogeniza-
tion, the suspension was centrifuged at 2500 rpm for 5 min. The
supernatant was transferred into vials for liquid scintillation
and counted on a g-counter (cytoplasm fraction). 500 ml of the
buﬀer was added to the cell pellet which was vortexed for 5
seconds, kept on ice for 10minutes and centrifuged at 8000 rpm
for 5 min. The supernatant was transferred into vials for liquid
scintillation and was counted on a g-counter (membrane frac-
tion). The remaining pellets were also counted by liquid
scintillation.
Drug transport assay using [3H]verapamil or [11C]MC150.
Colo320 cells were seeded on microporous polycarbonate
membrane lters (8.0 mm pore size, 6.5 mm diameter, Trans-
well™ 3422, Costar Corp., Cambridge, MD) at a density of 3 
104 cells per well. The cells were grown for 3 days. 1 h before the
experiment, medium on both apical (100 ml) and basolateral
side (600 ml) was replaced with RMPI complete medium. [3H]
Verapamil 0.2 ml (0.2 mCi) or [11C]MC150 (15 mL–6.6 kBq ml1)





















































































View Article OnlineMC111 to yield a nal concentration of 150 mM in the apical
side. The cells were incubated at 37 C at diﬀerent times. Aer
the incubation period, themedium from each side was removed
and transferred to vials for liquid scintillation and samples were
counted on a g-counter. The ratio of apical to basolateral was
calculated.
The chemistry and biology of this compound is already re-
ported in our previous paper.13
Neuroregeneration
DRG neuron harvest. The animal experiments were performed
according to the European Community guidelines for care and
use of animals. In particular animals were housed in air-
conditioned room with 12/12 h dark–light cycle, with food
and water ad libitum, in the approved facility at the University
of Bari. All animal procedures were performed in accordance
with the Guidelines for Care and Use of Laboratory Animals of
the “University of Bari (OPBA di Ateneo)” and the Italian
Ministry of Health. Adult male Sprague-Dawley rat (age of 6–8
months) was anaesthetized by isourane before decapitation
and the dorsal root ganglia (DRG) were gently pulled by its roots
and harvested from all accessible levels using ne forceps. DRG
were collected and placed on a Petri dish containing Ham's F12
medium at room temperature. The surrounding connective
tissue and nerve roots of the DRG were removed under the
microscope. Dissociated sensory neurons, from one rat for each
assay, were prepared as previously reported.14 The DRG neurons
were seeded on glass coverslips in 24 well plates pre-coated with
2 mg ml1 laminin in modied Bottenstein and Sato's Medium
(BSM; F12 medium containing 100 mM putrescine, 30 nM
sodium selenite, 20 nM progesterone, 1 mg ml1 BSA, 0.1 mg
ml1 transferrin, 0.01 mM cytosine arabinoside and 10 pM
insulin). Aer 2 h BSM incubation (negative control), BSM
supplemented with either NGF 1 mg ml1 or MC111 1 mM was
added to DRG culture which was incubated at 37 C, 5% CO2 for
72 h.
Immunocytochemistry. Before immunostaining, living cells
were examined and photographed under a Nikon DIAPHOT TS-
100 microscope. Images were digitized with 20 objective andThis journal is © The Royal Society of Chemistry 2018a Nikon Digital Video Camera E995 (Coolpix 995). Subsequently
the DRG neurons were xed with 4% (w/v) PFA/PBS solution for
30 min at RT. Aer three PBS washes, the cells were per-
meabilized in 0.02% Triton X-100/PBS for 20min. The cells were
then incubated with 5% normal horse serum (NHS) (Vector
Labs Inc.) for 1 h at RT to block non-specic binding sites. The
blocking solution was replaced with PBS containing primary
monoclonal mouse anti-bIII-tubulin antibody (Cell Signaling
Technology) at 1 : 1000 dilution for 24 h at 4 C. The cells were
nally incubated with secondary FITC horse anti-mouse anti-
bodies at 1 : 100 dilution (Vector Lab Ltd, UK) for 1 h at RT. The
coverslips were mounted with Vectashield on glass microscope
slides. Fluorescence was detected by an inverted Zeiss Axiovert
200 microscope equipped with epiuorescence. Cells were
imaged with CoolSNAP HQ CCD camera (Roper Scientic,
Trenton, NJ) using Metamorph soware (Universal Imaging
Corp., Downingtown, PA).
Neurite outgrowth analysis. Five independent culture experi-
ments were carried out. Images of eight elds per well were
taken. The number of cells sprouting neurites was determined by
examining the eld and counting cells with at least one neurite
equivalent to the length of a cell body diameter. This number was
expressed as a percentage of the total number of cells in the eld.
8 bit images were loaded into ImageJ (version 1.47) and indi-
vidual neurons, immunostained with anti-bIII-tubulin as
described above, were manually traced with NeuronJ plugin
(version version 1.4.2).15,16 The following parameters were
analyzed: (1) % of sensory neurons spouting neuritis respect to all
the sensory neurons present on the eld; (2) length of longest
neurite; (3) total number of processes grown in each eld from all
sensory neurons; (4) the total neurite length from all neurons in
the eld. Statistical analysis used to compare data from diﬀerent
groups was performed by Student's t-test. Values of p less than
0.05 or 0.01 were considered statistically signicant.
Conclusions
Neuroprotection and neuroreparative activities could be
considered the two diﬀerent faces of same medal where MC111
is the cohesive element. It represents a modern and smart drug
able to hit diﬀerent and synergistic targets of neurodegenerative
pathways (TLR4, P-gp and BCRP induction) and exerts neuro-
regenerative eﬀect although the molecular mechanism of the
last should be investigated. Another important advantage of
these results is that MC111 is the rst small molecule able to
give these combined eﬀects and further its lead optimization is
easy to carry out because of the simple structure of the ligand.
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